HOUSE BILL 2251

State of Washington 66th Legislature 2020 Regular Session

By Representatives Thai and Cody

Prefiled 12/19/19. Read first time 01/13/20. Referred to Committee on Health Care & Wellness.

- AN ACT Relating to the expiration date for notification of 1
- interchangeable biological product; dispensing an amending RCW
- 69.41.193; and providing an expiration date. 3
- BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON: 4
- 5 RCW 69.41.193 and 2015 c 242 s 4 are each amended to Sec. 1. 6 read as follows:
- 7 (1) Within five business days following the dispensing of a biological product, the dispensing pharmacist or the pharmacist's 8 designee must make an entry of the specific product provided to the 9 10 including either the name of the product and the 11 manufacturer or the federal food and drug administration's national 12 drug code, provided that the name of the product and the name of the manufacturer are accessible to a practitioner in an electronic
- 13
- 14 records system that can be electronically accessed by the patient's
- 15 practitioner through:

16

- (a) An interoperable electronic medical records system;
- 17 (b) An electronic prescribing technology;
- 18 (c) A pharmacy benefit management system; or
- 19 (d) A pharmacy record.
- 20 (2) Entry into an electronic records system, as described in 21 subsection (1) of this section, is presumed to provide notice to the

HB 2251 p. 1

- practitioner. Otherwise, the pharmacist must communicate to the practitioner the specific product provided to the patient, including the name of the product and manufacturer, using facsimile, telephone, electronic transmission, or other prevailing means.
- 5 (3) No entry or communication pursuant to this section is 6 required if:
 - (a) There is no interchangeable biological product for the product prescribed;
 - (b) A refill prescription is not changed from the product dispensed on the prior filling of the prescription; or
- 11 (c) The pharmacist or the pharmacist's designee and the 12 practitioner communicated before dispensing and the communication 13 included confirmation of the specific product to be provided to the 14 patient, including the name of the product and the manufacturer.
 - (4) This section expires August 1, ((2020)) 2025.

7

8

9

10

15

--- END ---

p. 2 HB 2251